Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases.

Régnier-Rosencher, E; Farhi, D; Lebrun, A; Salliot, C; Dougados, M; Dupin, N

Régnier-Rosencher, E; Farhi, D; Lebrun, A; Salliot, C; Dougados, M; Dupin, N.

Affiliation

Régnier-Rosencher E; Department of Dermatology, Hôpital Cochin, APHP, Université René Descartes Paris V, Paris, France.

Dermatology ; 224(1): 72-83, 2012.

Article in En | MEDLINE | ID: mdl-22487697

Subject(s)

Antirheumatic Agents/adverse effects; Biological Products/adverse effects; Rheumatic Diseases/drug therapy; Skin Diseases, Infectious/chemically induced; Tumor Necrosis Factor-alpha/adverse effects; Adalimumab; Aged; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Murine-Derived/adverse effects; Case-Control Studies; Cohort Studies; Etanercept; Female; Humans; Immunoglobulin G/adverse effects; Infliximab; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Risk Factors; Rituximab; Severity of Illness Index; Time Factors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Diseases, Infectious / Biological Products / Rheumatic Diseases / Tumor Necrosis Factor-alpha / Antirheumatic Agents Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Dermatology Journal subject: DERMATOLOGIA Year: 2012 Document type: Article Affiliation country: France Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google